You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Gene and Oligonucleotide Delivery System

    SBC: MOLECULAR EXPRESS, INC            Topic: NCATS

    DESCRIPTION provided by applicant The knockdown of targeted genes by anti sense oligonucleotides ODNS and genetic medicines collectively G MEDS holds promise for a variety of therapies The delivery of effective quantities of ODNS to specific cells however has proved to be challenging We propose here a novel approach to ODN delivery that involves enveloped virus like particles EVLPs ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a biomimetic small molecule therapeutic for neovascular retinal diseases

    SBC: EyeMedix, Inc.            Topic: N

    DESCRIPTION provided by applicant Retinal diseases including age related macular degeneration AMD diabetic retinopathy DR diabetic macular edema DME and retina vein occlusion RVO are the leading causes of vision loss and blindness in people over years old According to the NEI in nearly million people in the U S suffered from some form of these diseases whose prevalen ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a Behavioral Activation Mobile App for depressed Latinos

    SBC: MOUNTAINPASS TECHNOLOGY LLC            Topic: 102

    DESCRIPTION provided by applicant Treatment for depression is a core health disparity for Latinos in the U S Although U S Latinos are more likely than non Hispanic Whites to experience depression Alegria et al U S Latinos are less than half as likely as Whites to receive evidence based care for depression Lagomasino et al Latinos with elevated depressive symptoms are mos ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Development and testing of a behavioral activation mobile therapy for elevated depressive symptoms

    SBC: MOUNTAINPASS TECHNOLOGY LLC            Topic: 104

    DESCRIPTION provided by applicant Approximately of the population experiences elevated depressive symptoms Kubik et al Despite recent research suggesting that overall population mortality would be reduced by if the effects of subthreshold depression could be blocked completely the majority of individuals with elevated depressive symptoms never receive evidence based treat ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Developing Therapeutics That Target RAD To Treat Leukemia and Lymphoma

    SBC: Cyteir Therapeutics, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Developing novel RPPA for the detection of metastatic prostate cancer

    SBC: TYMORA ANALYTICAL OPERATIONS LLC            Topic: 102

    PROJECT SUMMARY Reverse phase protein arrayRPPAhas emerged as a promising antibody based highly quantitative proteomic technology suitable for profiling proteins in hundreds to thousands of patient samplesThe throughputsensitivityand cost effectiveness of RPPAtogether with its ability to deal with minuscule sample amountshave propelled applications of the technology in basicpreclinical and clinica ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Developing novel combination therapies for HSV genital infection.

    SBC: CASTERBRIDGE PHARMACEUTICALS INC            Topic: NIAID

    Herpes simplex virusesandHSVHSVcause a wide range of serious diseasesincluding oral genital lesionscorneal blindness and eczema herpeticumHSVand HSVare both transmitted sexually and can infect babies during birthTherapy for HSV relies primarily on nucleoside analogs such as acyclovirACVwhich are insufficiently effectiveand resistant viruses are becoming common among immunosuppressed personsTherefo ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Developing efficient and safe cell-permeable reprogramming peptides for generation of iPS cells.

    SBC: Vivoscript, Inc.            Topic: 200

    DESCRIPTION provided by applicant The groundbreaking discovery of induced pluripotent stem cells iPSCs has opened a new page for developing personalized cell based therapies against various devastating human diseases without ethical concerns of using human embryonic stem cells However the future clinical applications of iPSCs remain in doubt due to potential risks of undesired genomic alter ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Developing a Novel Digital Therapeutic for the Treatment of Generalized Anxiety Disorder

    SBC: GOBLUE INTERNATIONAL, LLC            Topic: 104

    Abstract Worry is a habitual thought process that is observed in individuals with anxiety disordersA leading theory posits that although worrying may be unpleasantthe immediate emotions that are avoided by concentrating on worry are often perceived as more aversiveegfearangergriefFrom a mechanistic perspectiveworry is thought to be learned and reinforced in a similar manner to other types of opera ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government